Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China; Center of Biomedical Big Data, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.
Clin Genitourin Cancer. 2019 Oct;17(5):e968-e980. doi: 10.1016/j.clgc.2019.05.011. Epub 2019 May 27.
Previous studies have revealed lymph node density (LND) to be an independent prognostic factor in cancer. However, data from 20 years ago failed to demonstrate the prognostic value of LND in node-positive renal-cell carcinoma (RCC). This study was undertaken to comprehensively investigate the prognostic value of LND in node-positive RCC.
Within the Surveillance, Epidemiology and End Results database, we accessed data on patients diagnosed with histologically confirmed node-positive RCC from 2004 to 2014. The cubic spline smoothing technique and Cox regression were used to evaluate the correlation between LND and cancer-specific mortality (CSM). The X-Tile program was used to identify the optimal cut point of LND in node-positive RCC. Robustness of the results in various subgroups was also explored. Univariable and multivariable analyses were performed to determine predictors of CSM. Sensitivity analyses were performed.
A total of 1750 node-positive RCCs were identified. We found a nonlinear positive correlation between the likelihood of CSM and LND. X-Tile analysis identified best cut point of LND as 35% with a maximum chi-square of 18.58. Every 10% increase in LND increased CSM by 5% (hazard ratio = 1.05; 95% confidence interval, 1.02-1.07; P < .0001), and LND ≥ 35% was associated with 41% increase in CSM (hazard ratio = 1.41; 95% confidence interval, 1.20-1.65; P < .0001) in fully adjusted Cox regression. Results of sensitivity analyses were consistent with those of the primary analysis.
LND is an independent prognostic factor in node-positive RCC and should be incorporated into the cancer staging system.
先前的研究表明,淋巴结密度(LND)是癌症的独立预后因素。然而,20 年前的数据未能证明 LND 在淋巴结阳性肾细胞癌(RCC)中的预后价值。本研究旨在全面探讨 LND 在淋巴结阳性 RCC 中的预后价值。
我们在 Surveillance、Epidemiology 和 End Results 数据库中,获取了 2004 年至 2014 年间经组织学证实为淋巴结阳性 RCC 患者的数据。采用三次样条平滑技术和 Cox 回归分析评估 LND 与癌症特异性死亡率(CSM)之间的相关性。使用 X-Tile 程序确定淋巴结阳性 RCC 中 LND 的最佳截断点。还探索了结果在各种亚组中的稳健性。进行单变量和多变量分析以确定 CSM 的预测因素。进行敏感性分析。
共确定了 1750 例淋巴结阳性 RCC。我们发现 CSM 的可能性与 LND 之间呈非线性正相关。X-Tile 分析确定 LND 的最佳截断点为 35%,最大卡方值为 18.58。LND 每增加 10%,CSM 增加 5%(风险比=1.05;95%置信区间,1.02-1.07;P<0.0001),LND≥35%与 CSM 增加 41%相关(风险比=1.41;95%置信区间,1.20-1.65;P<0.0001)在完全调整的 Cox 回归中。敏感性分析的结果与主要分析的结果一致。
LND 是淋巴结阳性 RCC 的独立预后因素,应纳入癌症分期系统。